A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder

Eric Hollander, A. Allen, R. P. Lopez, C. A. Bienstock, R. Grossman, L. J. Siever, L. Merkatz, D. J. Stein

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Background: Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality. Since anticonvulsant agents may be helpful in such symptomatology, we compared divalproex sodium with placebo in patients with borderline personality disorder. Method: A 10-week, parallel, double-blind design was conducted. Sixteen outpatients meeting Structured Clinical Interview for DSM-IV Axis II Personality Disorders criteria for borderline personality disorder were randomly assigned to receive placebo (N = 4) or divalproex sodium (N = 12). Change was assessed in global symptom severity (Clinical Global Impressions-Improvement Scale [CGI-I]) and functioning (Global Assessment Scale [GAS]) as well as in specific core symptoms (depression, aggression, irritability, and suicidality). Results: There was significant improvement from baseline in both global measures (CGI-I and GAS) following divalproex sodium treatment. A high dropout rate precluded finding significant differences between the treatment groups in the intent-to-treat analyses, although all results were in the predicted direction. Conclusion: Treatment with divalproex sodium may be more effective than placebo for global symptomatology, level of functioning, aggression, and depression. Controlled trials with larger sample sizes are warranted to confirm these preliminary results.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalJournal of Clinical Psychiatry
Volume62
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Borderline Personality Disorder
Valproic Acid
Aggression
Placebos
Depression
Impulsive Behavior
antineoplaston A10
Personality Disorders
Diagnostic and Statistical Manual of Mental Disorders
Anticonvulsants
Sample Size
Outpatients
Therapeutics
Interviews
Morbidity
Mortality

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Hollander, E., Allen, A., Lopez, R. P., Bienstock, C. A., Grossman, R., Siever, L. J., ... Stein, D. J. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62(3), 199-203.

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. / Hollander, Eric; Allen, A.; Lopez, R. P.; Bienstock, C. A.; Grossman, R.; Siever, L. J.; Merkatz, L.; Stein, D. J.

In: Journal of Clinical Psychiatry, Vol. 62, No. 3, 2001, p. 199-203.

Research output: Contribution to journalArticle

Hollander, E, Allen, A, Lopez, RP, Bienstock, CA, Grossman, R, Siever, LJ, Merkatz, L & Stein, DJ 2001, 'A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder', Journal of Clinical Psychiatry, vol. 62, no. 3, pp. 199-203.
Hollander, Eric ; Allen, A. ; Lopez, R. P. ; Bienstock, C. A. ; Grossman, R. ; Siever, L. J. ; Merkatz, L. ; Stein, D. J. / A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. In: Journal of Clinical Psychiatry. 2001 ; Vol. 62, No. 3. pp. 199-203.
@article{4be14543aea34047bd2d68b728e7497c,
title = "A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder",
abstract = "Background: Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality. Since anticonvulsant agents may be helpful in such symptomatology, we compared divalproex sodium with placebo in patients with borderline personality disorder. Method: A 10-week, parallel, double-blind design was conducted. Sixteen outpatients meeting Structured Clinical Interview for DSM-IV Axis II Personality Disorders criteria for borderline personality disorder were randomly assigned to receive placebo (N = 4) or divalproex sodium (N = 12). Change was assessed in global symptom severity (Clinical Global Impressions-Improvement Scale [CGI-I]) and functioning (Global Assessment Scale [GAS]) as well as in specific core symptoms (depression, aggression, irritability, and suicidality). Results: There was significant improvement from baseline in both global measures (CGI-I and GAS) following divalproex sodium treatment. A high dropout rate precluded finding significant differences between the treatment groups in the intent-to-treat analyses, although all results were in the predicted direction. Conclusion: Treatment with divalproex sodium may be more effective than placebo for global symptomatology, level of functioning, aggression, and depression. Controlled trials with larger sample sizes are warranted to confirm these preliminary results.",
author = "Eric Hollander and A. Allen and Lopez, {R. P.} and Bienstock, {C. A.} and R. Grossman and Siever, {L. J.} and L. Merkatz and Stein, {D. J.}",
year = "2001",
language = "English (US)",
volume = "62",
pages = "199--203",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder

AU - Hollander, Eric

AU - Allen, A.

AU - Lopez, R. P.

AU - Bienstock, C. A.

AU - Grossman, R.

AU - Siever, L. J.

AU - Merkatz, L.

AU - Stein, D. J.

PY - 2001

Y1 - 2001

N2 - Background: Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality. Since anticonvulsant agents may be helpful in such symptomatology, we compared divalproex sodium with placebo in patients with borderline personality disorder. Method: A 10-week, parallel, double-blind design was conducted. Sixteen outpatients meeting Structured Clinical Interview for DSM-IV Axis II Personality Disorders criteria for borderline personality disorder were randomly assigned to receive placebo (N = 4) or divalproex sodium (N = 12). Change was assessed in global symptom severity (Clinical Global Impressions-Improvement Scale [CGI-I]) and functioning (Global Assessment Scale [GAS]) as well as in specific core symptoms (depression, aggression, irritability, and suicidality). Results: There was significant improvement from baseline in both global measures (CGI-I and GAS) following divalproex sodium treatment. A high dropout rate precluded finding significant differences between the treatment groups in the intent-to-treat analyses, although all results were in the predicted direction. Conclusion: Treatment with divalproex sodium may be more effective than placebo for global symptomatology, level of functioning, aggression, and depression. Controlled trials with larger sample sizes are warranted to confirm these preliminary results.

AB - Background: Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality. Since anticonvulsant agents may be helpful in such symptomatology, we compared divalproex sodium with placebo in patients with borderline personality disorder. Method: A 10-week, parallel, double-blind design was conducted. Sixteen outpatients meeting Structured Clinical Interview for DSM-IV Axis II Personality Disorders criteria for borderline personality disorder were randomly assigned to receive placebo (N = 4) or divalproex sodium (N = 12). Change was assessed in global symptom severity (Clinical Global Impressions-Improvement Scale [CGI-I]) and functioning (Global Assessment Scale [GAS]) as well as in specific core symptoms (depression, aggression, irritability, and suicidality). Results: There was significant improvement from baseline in both global measures (CGI-I and GAS) following divalproex sodium treatment. A high dropout rate precluded finding significant differences between the treatment groups in the intent-to-treat analyses, although all results were in the predicted direction. Conclusion: Treatment with divalproex sodium may be more effective than placebo for global symptomatology, level of functioning, aggression, and depression. Controlled trials with larger sample sizes are warranted to confirm these preliminary results.

UR - http://www.scopus.com/inward/record.url?scp=0035060315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035060315&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 199

EP - 203

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3

ER -